Targeting capture and eradicate circulating tumor cells by activated platelet derived vehicle for inhibiting triple-negative breast cancer metastasis

作者：Hongmei Zhang, Jinlan Jiao, Yue Long, Lina Zhou, Yanmin Lv, Wenqian Wei, Yuxiang Sun, Hao Han, Changrong Chen, Yun Zhu, Weijie Zhang · 发表于：Materials Today Bio · 年份：2025 · DOI：10.1016/j.mtbio.2025.101597 · 被引用次数：1 · 研究领域：Nanoplatforms for cancer theranostics、Cancer Cells and Metastasis、Cancer, Stress, Anesthesia, and Immune Response

Circulating tumor cells (CTCs) are cardinal intermediaries in the metastatic cascade, particularly in triple-negative breast cancer (TNBC), owing to their high-affinity interactions that bolster survival and dissemination. Addressing this pivotal mechanism, we have developed APEVs@DOX, a pioneering biomimetic delivery system. Utilizing activated platelet membranes as a scaffold, APEVs@DOX recapitulates the natural affinity between platelets and CTCs, enabling targeted delivery of doxorubicin. Our results, substantiated by meticulous in vitro and in vivo experimentation, revealed 78 % reduction in lung metastasis nodules in murine models relative to controls, affirming APEVs@DOX's proficiency in CTCs capture and eradication. This study not only illuminates the potential of CTCs-targeted therapies in the precision medicine armamentarium for TNBC but also contributes empirical data to guide the strategic design of anti-metastatic interventions. The therapeutic impact of APEVs@DOX in curtailing metastatic spread offers a beacon of hope for advancing TNBC treatment paradigms. • APEVs@DOX: Biomimetic system targets CTCs, inhibits TNBC metastasis using platelet membranes. • APEVs@DOX cuts lung metastasis by >70% in mice, proving efficacy against TNBC spread. • CTC-targeted therapies advance precision medicine, guiding tailored anti-metastatic TNBC strategies. • APEVs@DOX captures CTCs, halts metastatic growth, offering dual-action TNBC lung metastasis suppression.